A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

ABSTRACTEpithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been challenging because it is also highly expressed in...

Full description

Bibliographic Details
Main Authors:	Gerhard Frey, Ana Paula G. Cugnetti, Haizhen Liu, Charles Xing, Christina Wheeler, Hwai Wen Chang, William J. Boyle, Jay M. Short
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody engineering bispecific antibody conditionally active EpCAM protein engineering T-cell engager
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2322562

Similar Items

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
by: Emily Maria Ploeg, et al.
Published: (2023-07-01)

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth
by: Vita Golubovskaya, et al.
Published: (2023-05-01)

Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
by: Guanjie Li, et al.
Published: (2022-06-01)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
by: Stefan Schönberger, et al.
Published: (2020-05-01)

CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager
by: Andisheh Bagheri, et al.
Published: (2022-03-01)

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
by: Joanna Macdonald, et al.
Published: (2018-01-01)

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
by: Min Wei, et al.
Published: (2022-11-01)

Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy
by: Seyed-Ali Hosseinian, et al.
Published: (2018-08-01)

IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer
by: Lei Wang, et al.
Published: (2022-02-01)

Destabilization of EpCAM dimer is associated with increased susceptibility towards cleavage by TACE
by: Tomaž Žagar, et al.
Published: (2021-05-01)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
by: Serena H. Chen, et al.
Published: (2021-09-01)

A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG<sub>2a</sub>-f) Exerts Antitumor Activity in Xenograft Model
by: Teizo Asano, et al.
Published: (2022-11-01)

EpCAM as a novel therapeutic target for hepatocellular carcinoma
by: Vasanthakumar S, et al.
Published: (2017-07-01)

Absence of EpCAM in cervical cancer cells is involved in sluginduced epithelial‐mesenchymal transition
by: Xian Liu, et al.
Published: (2021-03-01)

Digital scoring of EpCAM and slug expression as prognostic markers in head and neck squamous cell carcinomas
by: Henrik Schinke, et al.
Published: (2021-04-01)

Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
by: Ya-feng Lv, et al.
Published: (2023-12-01)

EpCAM (CD326) Regulates Intestinal Epithelial Integrity and Stem Cells via Rho-Associated Kinase
by: Takeshi Ouchi, et al.
Published: (2021-01-01)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
by: Anzhelika Vorobyeva, et al.
Published: (2020-05-01)

Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside
by: Yiyang Liu, et al.
Published: (2022-11-01)

EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients
by: Yang Liao, et al.
Published: (2022-04-01)

Dynamic Expression of EpCAM in Primary and Metastatic Lung Cancer Is Controlled by Both Genetic and Epigenetic Mechanisms
by: Yeting Cui, et al.
Published: (2022-08-01)

Targeted EpCAM-binding for the development of potent and effective anticancer proteins
by: Zhao Liu, et al.
Published: (2023-05-01)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
by: Tianqi Xu, et al.
Published: (2021-08-01)

Anti-EpCAM functionalized graphene oxide vector for tumor targeted siRNA delivery and cancer therapy
by: Si Chen, et al.
Published: (2021-09-01)

Current View on EpCAM Structural Biology
by: Aljaž Gaber, et al.
Published: (2020-05-01)

EpCAM- and/or NCAM-Expressing Hepatocellular Carcinoma in Which Behavior of Hepatic Progenitor Cell Marker-Positive Cells Are Followed
by: Atsunori Tsuchiya, et al.
Published: (2019-03-01)

EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
by: Chaoyu Zhang, et al.
Published: (2022-05-01)

Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis
by: Chi-Chiu Lee, et al.
Published: (2023-08-01)

Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
by: Martowicz Agnieszka, et al.
Published: (2012-10-01)

EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer
by: Arijit Mal, et al.
Published: (2021-01-01)

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
by: Anzhelika Vorobyeva, et al.
Published: (2020-10-01)

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment
by: Suphalak Khamruang Marshall, et al.
Published: (2022-06-01)

Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins
by: Chuan-Jin Wu, et al.
Published: (2020-04-01)

Photo-functionalized TiO2 film for facile immobilization of EpCAM antibodies and efficient enrichment of circulating tumor cells
by: Huan Deng, et al.
Published: (2023-02-01)

Fraction of MHCII and EpCAM expression characterizes distal lung epithelial cells for alveolar type 2 cell isolation
by: Koichi Hasegawa, et al.
Published: (2017-08-01)

Ultra-Sensitive Automated Profiling of EpCAM Expression on Tumor-Derived Extracellular Vesicles
by: Pouya Amrollahi, et al.
Published: (2019-12-01)

Diagnostic and Prognostic Values of Serum EpCAM, TGM2, and HE4 Levels in Endometrial Cancer
by: Ting Lan, et al.
Published: (2020-09-01)

Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk
by: Khadijeh Barzaman, et al.
Published: (2022-08-01)

A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression
by: Yu Hu, et al.
Published: (2019-07-01)

EpCAM Is Essential to Maintaining the Immune Homeostasis of Intestines via Keeping the Expression of pIgR in the Intestinal Epithelium of Mice
by: Zili Lei, et al.
Published: (2022-04-01)